|
Valoración de DCF de Cohbar, Inc. (CWBR)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
CohBar, Inc. (CWBR) Bundle
¡Mejore sus opciones de inversión con la calculadora DCF de Cohbar, Inc. (CWBR)! Obtenga datos financieros reales para Cohbar, ajuste las proyecciones y gastos de crecimiento, y observe instantáneamente cómo estos cambios afectan el valor intrínseco de Cohbar, Inc. (CWBR).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -15.1 | -12.3 | -15.4 | -15.4 | -12.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .1 | .1 | .2 | .1 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -15.2 | -12.4 | -15.6 | -15.5 | -12.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 22.2 | 12.6 | 21.0 | 26.2 | 15.7 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .2 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | -21.4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.1 | .4 | .7 | .4 | .2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.4 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
| EBITAT | -15.2 | -13.0 | -14.0 | -15.5 | -12.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -14.4 | -13.7 | -13.6 | 5.6 | -33.5 | -.2 | .0 | .0 | .0 | .0 |
| WACC, % | 10.97 | 10.97 | 10.97 | 10.97 | 10.97 | 10.97 | 10.97 | 10.97 | 10.97 | 10.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -6 | |||||||||
| Equity Value | 6 | |||||||||
| Diluted Shares Outstanding, MM | 3 | |||||||||
| Equity Value Per Share | 2.00 |
What You Will Get
- Real CWBR Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess CohBar’s future performance.
- User-Friendly Design: Designed for professionals while remaining easy to use for newcomers.
Key Features
- Real-Life CWBR Data: Pre-filled with CohBar’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review CohBar, Inc.'s (CWBR) pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust assumptions.
- Step 5: Evaluate the outputs and apply the results for your investment strategies.
Why Choose This Calculator for CohBar, Inc. (CWBR)?
- Designed for Experts: A sophisticated tool favored by analysts, CFOs, and industry consultants.
- Accurate Data: CohBar’s historical and projected financials are preloaded for reliable insights.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth user experience.
Who Should Use This Product?
- Investors: Accurately assess CohBar, Inc.’s (CWBR) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial analysis and reporting related to CohBar, Inc. (CWBR).
- Consultants: Easily modify the template for valuation reports tailored to clients involving CohBar, Inc. (CWBR).
- Entrepreneurs: Acquire knowledge about financial modeling practices employed by leading biotech firms like CohBar, Inc. (CWBR).
- Educators: Implement it as an educational resource to illustrate valuation techniques relevant to CohBar, Inc. (CWBR).
What the Template Contains
- Preloaded CWBR Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.